Advance cardiovascular disease research with high plex protein profiling for biomarker discovery

Target 7,000 proteins from a 55 μl sample to identify novel protein signatures

Discover relevant biomarkers related to cardiac health and disease for prevention, diagnostics, and drug development

Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Identifying novel and early-stage biomarkers is important in predicting and preventing the significant morbidity and mortality associated with CVD. High content analysis of the human plasma proteome is facilitating the possibility for novel biomarker discoveries. This, combined with increasing capacity for analysis of large data sets, opens a world of possibilities for improving cardiovascular care with a more personalized medicine approach.

Look deeper with the SomaScan platform

Speedometer-like graphic

Multiplex, high-throughput proteomics

Screen up to 7,000 proteins per sample and conduct high-throughput analysis of >1,000 samples simultaneously.

Magnifying glass

Sensitive detection

Detect and quantify a wide dynamic range of proteins (from fmol – μmol) in complex sample types such as serum and plasma.

Icon of many hexagons being repeated

Reproducible

Obtain consistent and reproducible inter- and intraassay results for data analysis and comparison.

Advanced proteomics offerings in CVD

The SomaScan Platform is available in multiple formats, each providing unique data outputs to fast-track your CVD research.

SomaScan Assay

With the ability to profile 7,000 proteins simultaneously and in easily accessible samples such as blood and urine, the SomaScan Assay is well suited to measuring low and highly abundant proteins to identify CVD biomarkers.

Learn more

SomaScan Panels

These custom panels can be individualized from our menu of 7,000 protein analytes. The assay is also offered as a cardiac panel focused on 953 CVD-relevant proteins, in addition to other curated panels for inflammation and metabolic diseases.

Learn more

SomaSignal™ Tests

Monitor clinical metrics including those associated with CVD such as body fat percentage, lean body mass, cardiorespiratory fitness, and heart failure-specific tests.

Learn more

In one of the largest proteomics studies ever conducted, scientists from 18 organizations across the world used the SomaScan Assay to create and validate a 27-protein clinical test model that accurately predicted the 4-year likelihood of myocardial infarction, heart failure, stroke, or death. This model elucidated the underlying biology associated with clinical risk factors and has the potential for consideration as a “universal” surrogate endpoint for CVD risk. (A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk | Science Translational Medicine)

Additional resources

See relevant publications in our interactive viewer

Explore external publications in our interactive viewer